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Abstract
Familial Adenomatous Polyposis (FAP) is an inheritable predisposition for the occurrence of numerous polyps
in the large intestine. In about 50% of all patients, the occurrence of the disease is conditioned by heterozygotic
mutations of the APC gene.  Screening for genetic factors in persons without mutations in the APC gene led to
the identification of homozygotic mutations of the MYH gene as the cause of the appearance of the polyposis
form which is characterized by recessive heritability and a milder course than in the case of the classic form of
the disease. The authors examined 90 persons from the DNA bank of patients with FAP from the Institute of
Human Genetics of the Polish Academy of Sciences in Poznañ in whom no mutations in the APC gene were
detected. Two of the most frequent mutations of the MYH gene (Y165C and G382D) were found to be
heterozygous in 13% of patients and no other mutations in this gene coding sequence were observed. In the
group with heterozygotic occurrence of the mutation in the MYH gene, the disease phenotype was not milder
in comparison with the entire examined group and the mean age of the disease manifestation was even lower.
This observation allows one to conclude that the employed methods of mutation screening were correct and,
in the case of the examined group, the mutation ratio of the MYH gene does not precondition the occurrence
of the disease, but it cannot be excluded that it may modify its phenotype. The obtained results indicate that the
criteria applied during the process of FAP qualification are more rigorous than those applied in other countries.
MYH Gene Status in Polish FAP Patients without APC Gene Mutations
Marzena Skrzypczak1,2, Marta Podralska1, Wolfram Heinritz2, Ursula G. Froster2, Daniel Lipiñski1, Ryszard S³omski2, 
Andrzej P³awski1
1Institute of Human Genetics, Polish Academy of Sciences, Poznañ, Poland; 2Institute of Human Genetics, University of Leipzig, Leipzig, Germany
Key words:  MYH,  Famil ial  Polyposis ,  Poland
Corresponding author:  Andrzej  P³awski ,  Ins t i tute  of  Human Genet i cs ,  Pol i sh  Academy of  Sc iences ,  u l .  S trzeszyñska 32,
60-479 Poznañ,  Poland,  te l .  +48 61 823 30 11,  fax  +48 61 823 32 35,  e -mai l:  andp@man.poznan.pl
Submit ted:  3  December 2005
Accepted:  10 January 2006
Introduction
Familial adenomatous polyposis is characterized
by the appearance of numerous polyps in the large
intestine. Untreated polyps lead to the development
of colorectal cancer before age 50 years. The
correlation between mutations of the APC gene and
the occurrence of familial adenomatous polyposis was
described in 1991 [1, 2] and since then mutations of
the APC gene have been investigated in many research
centres identifying various types of mutations. In the
case of the largest group, comprising 1,164 families
from Germany, mutations were identified in 54% of
families [3].
The latest investigations point to a correlation between
homozygotic mutations of the MYH gene alleles and the
occurrence of the recessive form of polyposis of the large
intestine. The product of the MYH gene is an endonuclease
of the DNA repair system by way of base excision and
recognises non-pairings of the A/G, A/GO and A/C types
[4]. The defect of both gene alleles gives a status of somatic
mutations of the APC gene in the form of G:C > T:A pairs
which change GAA codons into TAA. The APC gene is
particularly sensitive to the appearance of mutations
Table 1. DHPLC conditions for analyses of exons 7 and 13 of the MYH gene
Exon 7 (Y165C)
Time (min) % Buffer A % Buffer B Oven temp.
loading 0.0 55.9 44.1 62.8oC
start gradient 0.5 50.9 49.1
stop gradient 5.0 41.9 58.1
Exon 13 (G382D)
Time (min) %A AB
loading 0.0 53.9 46.1 65.6oC
start gradient 0.5 48.5 51.5
stop gradient 5.0 39.9 60.1
Buffer A:    50 ml M TEAA, 250 µl AcN → 1 L H20
Buffer B:    50 ml M TEAA, 250 ml AcN → 1 L H20
developing as a result of the lack of functions in the MYH
locus because 216 GAA codons occur in it [5]. The MYH
gene is located on chromosome 1p32-34, consists of 16
exons and encompasses 7,100 base pairs [5]. The two
most common mutations, Y165C and G382D, which
occur in the European population with a frequency of 1%,
are observed in 80% patients with mutations of both alleles
of the MYH gene [6-8]. Data concerning the phenotype of
mutation carriers in the MYH gene are not very extensive.
In the majority, the described mutation carriers in the MYH
gene are characterized by a milder course of the disease
and a smaller number of polyps than is the case in the
classic FAP. The phenotype is similar to attenuated
adenomatous polyposis of the colon (AAPC) and the
number of polyps does not exceed 1,000. Homozygous
mutations of the MYH gene are associated with the
occurrence of the disease in 8% of patients in whom
mutations in the APC gene have not been discovered [6].
In samples collected in our DNA bank of families
with FAP, mutations were identified in 50% of families
[9]. In the course of this study, 90 FAP patients with no
mutation identified in the APC gene were examined
with regard to the occurrence of mutations in the MYH
gene using the PCR-HD and PCR-SSCP methods to
investigate the coding sequence of the APC gene. We
determined the frequency occurrence of the G382M
and Y165C mutations as well as the V22M
polymorphism described earlier.
Patients and methods
The examined group comprised patients with
diagnosed large intestine polyposis derived from the
DNA bank of patients with familial polyposis from the
Institute of Human Genetics, Polish Academy of
Sciences in Poznañ. The group of 90 patients with no
mutation identified in the APC gene derived from
different parts of Poland. The age when the first disease
symptoms occurred ranged from 10 to 50 years with
an average age of 29.5 at symptom appearance. In
the examined group, 12 cases occurred in the studied
families de novo (typical FAP phenotype), 16 patients
represented cases of the attenuated form of the disease
with a small number of polyps, and the remainding
were cases of the classical form of familial polyposis
with the number of polyps exceeding 1,000.
Molecular methods
DNA was extracted from peripheral blood cells by
the classical phenol purification method. The MYH gene
fragments were amplified using primers and PCR
reaction condition as previously described by Al-Tassan
[10]. The amplified fragments of the MYH gene were
screened for mutations using heteroduplex analysis (HD)
and single strand conformational polymorphism (SSCP)
methods [11]. DNA fragments showing heteroduplex in
HD analysis or additional pattern in SSCP analysis were
subjected to direct PCR product sequencing and
analysed using the Perking Elmer ABI 377 DNA
sequencer according to the manufacturer’s specifications.
For V22M screening, the PCR product of exon 2 of the
MYH gene was digested with -Nco I endonuclease.
Exons 7 and 13 were screened for Y165C and G382D
variants using the DHPLC method. The amplified
fragments were denatured at 95oC for 5 min. and slowly
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annealed from 95oC to 65oC over 30 min. to promote
heteroduplex formation. The PCR products were injected
into the column and eluted using an increasing
acetonitryle gradient. The conditions distinguishing the
Y165C (exon 7) and the G382D (exon 13) variants were
established, Figure 1. The DHPLC parameters for those
separations are presented in Table 1.
Results and discussion
96 probands without mutation in the APC gene were
examined for the occurrence of mutation in the MYH
gene. The main emphasis in the performed studies was
placed on the frequency of occurrence of the already
described pathogenic substitutions Y165C and G382D.
For easy variant identification, conditions of the DHPLC
examination were optimized for the above two mutations.
The third variant, V22M, which is not considered
pathogenic, was examined using restriction analysis. In
the examined group, 9 cases of G382C substitution, 4
cases of Y165C and 5 cases of V22M were recorded.
Examination of the MYH gene coding sequence using
PCR-HD and PCR-SSCP methods led to the conclusion
that the MYH gene did not contain polymorphic variants
in the remaining part of the coding sequence. The
above-mentioned frequent mutations failed to occur as
homozygous (Table 2). One of the carriers of the Y165C
mutation with the classical form of familial polyposis was
also the carrier of the G169D mutation in the second
allele of the MYH gene. G169D is a novel change in
the MYH gene not described before. A change in amino
acid sequence can lead to a phenotypic effect but the
pathogenicity of this variant cannot be determined at
this stage. This mutation is also observed in the patient’s
brother with clinical symptoms and phenotype of classical
form of FAP. In the case of both affected brothers,
numerous polyps were observed to appear in the fourth
decade of their lives. In 12 persons in whom one of the
pathogenic mutations occurred, the mild form of the
disease was diagnosed in 3 cases, whereas in 9 cases
the diagnosed form was that of classical FAP. The age
of appearance of the disease in this group was quite low
and the youngest patients were only 12 years old when
Table 2. Genetic variants observed in the MYH gene in Polish FAP patients
No. Proband Mutation Genetic variant Phenotype
1 9039 494A>G 506G>A Y165C G169D FAP 
2 9121 494A>G Y165C FAP
3 9160 494A>G Y165C FAP
4 9164 494A>G Y165C FAP
5 9056 1145G>A G382D AFAP
6 9101 1145G>A G382D FAP 
7 9109 1145G>A G382D FAP
8 9113 1145G>A G382D FAP
9 9120 1145G>A G382D FAP
10 9132 1145G>A G382D FAP
11 9133 1145G>A G382D AFAP
12 9140 1145G>A G382D AFAP
13 9157 1145G>A G382D FAP 
14 9052 64G>A V22M FAP
15 9054 64G>A V22M FAP
16 9055 64G>A V22M FAP
17 9072 64G>A V22M FAP
18 9163 64G>A V22M AFAP
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the first symptoms of the disease were identified. The
percentage of the mild form of the polyposis did not
differ significantly from the frequency observed in the
entire examined group. The phenotype of the classical
form of the disease observed in this group failed to
correlate with the earlier observations about the milder
course of the disease in the carriers of homozygotic
mutation in the MYH gene [10, 12]. This observation
reveals the absence of predisposition to the disease by
mutations in the MYH gene in the homozygotic system
as confirmed by screening for the mutation using PCR-
HD and PCR-SSCP methods. In addition, the average
age of occurrence of the disease in the group in which
one of the pathogenic mutations or the V22M
polymorphism occur is by 10 years lower than in the
entire examined population. It is true that the size of the
examined group is not big, but it cannot be excluded
that these mutations may have a modifying effect on
other genetic factors predisposing to the disease. The
results indicate that in our group of patients with
diagnosed FAP without mutation in the APC gene, the
proportion of the mutation in the MYH gene exerts a
very small effect on preconditioning the disease. 
This situation may be associated with the fact that
our physicians may use more stringent criteria in the
course of qualifications for examinations than doctors
in other groups. The stringent criteria used in the
qualification of patients as having FAP syndrome may
be one explanation of the above observations.
This work was supported by grant 2PO5A10728
from the Ministry of Science and Information Society
Technologies awarded to AP.
Fig. 1. Flourograms of DHPLC analysis of MYH gene: A. Exon 7 of MYH gene, grey negative control, black Y165C; B. Exon 13 of MYH
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